Drug resistance-associated substitutions identified in HCV genes

Gastroenterology 2017

View Abstract

In Press: Patterns of Resistance-associated Substitutions in Patients With Chronic HCV Infection Following Treatment with Direct-acting Antivirals

DOI: http://dx.doi.org/10.1053/j.gastro.2017.11.007

Commentary

Drug resistance-associated substitutions identified in HCV genes

Last Updated: 2017-11-24

By Marilynn Larkin

NEW YORK (Reuters Health) - In patients who fail direct-acting antiviral therapy for hepatitis C virus (HCV) infection, resistance-associated substitutions (RASs) vary by HCV genotype and subtype and with different classes of drugs - a finding that might be used to select salvage therapies, researchers suggest.

"Little is known about (genetic) substitutions that mediate resistance of HCV to direct-acting antivirals, due to the small number of patients with treatment failure in approval studies," note Dr. Christoph Sarrazin of the University of Frankfurt, in Germany, and colleagues.
To investigate, the team analyzed samples from patients who had HCV infection with genotypes 1 to 6 for RASs in HCV genes (NS3, NS5A, NS5B) that are targeted by direct-acting antivirals.
Continue to article - http://www.chronicliverdisease.org/reuters/article.cfm?article=20171124Other832489063